Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.
D000818:Animals; D002543:Cerebral Hemorrhage / Q000150:complications*; D004146:Dioxanes / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D004361:Drug Tolerance; D064420:Drug-Related Side Effects and Adverse Reactions; D065128:Endothelin Receptor Antagonists; D006801:Humans; D011725:Pyridines / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D017466:Receptors, Endothelin / Q000378:metabolism; D013449:Sulfonamides / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D013777:Tetrazoles / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D020301:Vasospasm, Intracranial / Q000188:drug therapy* / Q000209:etiology*
D004146:Dioxanes; D065128:Endothelin Receptor Antagonists; D011725:Pyridines; D011743:Pyrimidines; D017466:Receptors, Endothelin; D013449:Sulfonamides; D013777:Tetrazoles; C109641:clazosentan